Short Interest in ProPhase Labs, Inc. (NASDAQ:PRPH) Drops By 27.1%

ProPhase Labs, Inc. (NASDAQ:PRPH) was the recipient of a large decline in short interest in January. As of January 31st, there was short interest totalling 84,900 shares, a decline of 27.1% from the January 15th total of 116,400 shares. Based on an average daily volume of 621,700 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of PRPH. SVB Wealth LLC purchased a new stake in ProPhase Labs during the 4th quarter worth about $36,000. Warberg Asset Management LLC purchased a new stake in ProPhase Labs during the 4th quarter worth about $77,000. Perritt Capital Management Inc lifted its holdings in ProPhase Labs by 129.1% during the 4th quarter. Perritt Capital Management Inc now owns 190,000 shares of the company’s stock worth $144,000 after buying an additional 107,068 shares during the last quarter. Geode Capital Management LLC lifted its holdings in ProPhase Labs by 26.6% during the 4th quarter. Geode Capital Management LLC now owns 203,528 shares of the company’s stock worth $154,000 after buying an additional 42,793 shares during the last quarter. Finally, Sheets Smith Wealth Management purchased a new stake in ProPhase Labs during the 4th quarter worth about $158,000. 9.45% of the stock is owned by institutional investors and hedge funds.

ProPhase Labs Price Performance

PRPH traded down $0.02 on Friday, hitting $0.33. 12,660,706 shares of the company were exchanged, compared to its average volume of 1,228,625. ProPhase Labs has a twelve month low of $0.22 and a twelve month high of $7.48. The company has a current ratio of 1.47, a quick ratio of 1.33 and a debt-to-equity ratio of 0.48. The firm has a 50-day moving average price of $0.55 and a two-hundred day moving average price of $1.54.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on ProPhase Labs in a research note on Sunday, February 9th. They set a “sell” rating for the company.

ProPhase Labs Company Profile

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.